The conventional model of developing one vaccine per pathogen may be the single greatest structural vulnerability in global pandemic preparedness. If a cross-protective platform could be deployed before a novel zoonotic virus achieves widespread transmission, the calculus of pandemic response changes fundamentally — from reactive containment to proactive defense. That is the promise this review systematically evaluates.
This comprehensive analysis maps the scientific landscape of pan-pathogen vaccinology — vaccines engineered to elicit immunity across multiple related or unrelated pathogens simultaneously. The authors draw on comparative genomics, evolutionary biology, and immunoinformatics to identify conserved antigenic epitopes that remain stable across pathogen variants, making them prime targets for broad-spectrum vaccine design. The review examines four classes of immune mechanisms relevant to cross-protection: CD8+ and CD4+ T-cell responses, broadly neutralizing antibodies (bnAbs), mucosal immunity, and trained innate immunity — notably analyzing how these arms interact rather than treating them in isolation. Platforms assessed include mRNA constructs, viral vector systems, protein subunit formulations, and nanoparticle-based delivery, each with distinct cross-reactivity profiles. Case studies anchor the discussion in practical precedent, particularly Nipah virus candidate vaccines and the rVSV-Ebola platform.
The intellectual ambition here is considerable, but the limitations are equally significant. This is a review article, not a clinical trial, meaning its core value lies in synthesis rather than new data generation. The pan-pathogen concept remains largely in preclinical or early-phase territory; no fully validated pan-coronavirus or pan-influenza vaccine has yet achieved licensure. The One Health framing — integrating human, animal, and environmental health — is conceptually sound and increasingly recognized by WHO and the Lancet, but operationalizing it across regulatory jurisdictions remains a practical challenge. For health-conscious adults, the takeaway is that the scientific infrastructure for next-generation pandemic vaccines is being built now, and the decisions made about conserved epitope targets and platform technology in the coming decade will determine how quickly the world can respond to the pathogen that doesn't yet have a name.